Last edition
News about "Actio Biosciences "
Jazz Pharmaceuticals Acquires Actio Biosciences
Jazz Pharmaceuticals acquires ABS-1230, a first-in-class precision therapy for KCNT1-related epilepsy, strengthening its rare disease pipeline.
Actio Biosciences | 16/09/2026 | By News Bureau
Jazz Pharmaceuticals has agreed to acquire Actio Biosciences for USD 820 million upfront and up to USD 500 million in contingent payments, expanding its rare epilepsy pipeline with investigational therapy ABS-1230.
Actio Biosciences | 12/08/2026 | By News Bureau | 116
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy